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ABSTRACT
Objectives: Military-related trauma can be difficult to
treat. Evaluating longer term responses to treatment
and identifying which individuals may need additional
support could inform clinical practice. We assessed
1-year outcomes in UK veterans treated for post-
traumatic stress disorder (PTSD).
Design: Within-participant design.
Setting: The intervention was offered by Combat
Stress, a mental health charity for veterans in the UK.
Participants: The sample included 401 veterans who
completed a standardised 6-week residential treatment.
Of these, 268 (67%) were successfully followed up a
year after the end of treatment.
Methods: A range of health outcomes were collected
pretreatment and repeated at standard intervals post-
treatment. The primary outcome was severity of PTSD
symptoms, and secondary outcomes included
measures of other mental health difficulties
(depression, anxiety and anger), problems with
alcohol, and social and occupational functioning.
Results: Significant reductions in PTSD severity were
observed a year after treatment (PSS-I: −11.9, 95% CI
−13.1 to −10.7). Reductions in the secondary
outcomes were also reported. Higher levels of post-
treatment functional impairment (0.24, 95% CI 0.08 to
0.41) and alcohol problems (0.18, 95% CI 0.03 to
0.32) were associated with poorer PTSD treatment
response at 12 months.
Conclusions: This uncontrolled study suggests the
longer term benefits of a structured programme to
treat UK veterans with PTSD. Our findings point to the
importance of continued support targeted for particular
individuals post-treatment to improve longer term
outcomes.
INTRODUCTION
Treatments for veterans with post-traumatic
stress disorder (PTSD) seem to be less effect-
ive than for matched populations,1–3 and vet-
erans with PTSD are at increased risk of high
levels of dysfunction and social exclusion.4–6
Furthermore, PTSD has been shown to
create a higher ﬁnancial burden to the
society than any other mental health condi-
tions in veterans.7 Understanding which
treatments are effective for this group is a
priority.
Following the conﬂicts in Iraq and
Afghanistan, large-scale epidemiological
studies explored the health outcomes within
the Coalition forces involved. Studies of US
military personnel have observed higher
rates of PTSD in individuals who have served
on deployments to Iraq and Afghanistan.8 9
A different picture has emerged in the UK
military, with no difference in rates of PTSD
observed between those who deployed or
not, with rates in both groups of 4%.10
Higher rates of PTSD were, however,
observed for groups of UK military person-
nel who had deployed either into combat
roles or were reservists.10 Evidence from US
military samples suggests an increase in
PTSD rates as time since deployment
increases, a ﬁnding that has not been repli-
cated to date in UK samples where only
modest increases have been noted.10 11 The
studies conducted within the UK Armed
Forces were last reported in 2010, and little is
known about whether the prevalence rates of
PTSD have changed over the intervening
years. Irrespective of the overall prevalence
Strengths and limitations of this study
▪ This study reports treatment response a year
after the completion of treatment.
▪ The study sampled from a national treatment
programme offered by the largest provider of
interventions for veterans with post-traumatic
stress disorder in the UK.
▪ Of the participants, 67% were successfully con-
tacted a year after treatment.
▪ The study did not employ a randomised con-
trolled trial design, so there are limitations about
the conclusions that can be drawn.
▪ Little was known about the treatment experiences
of participants prior to them enrolling for
treatment.
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rates of mental illness in UK personnel, the number of
referrals from veterans seeking support has increased
considerably over time, especially among those who
served in Afghanistan.12
We have previously reported on treatment response in
UK veterans with PTSD attending Combat Stress (CS).
CS is a national charity in the UK that provides mental
health services to veterans. Outside of the National
Health Service (NHS), CS is the largest provider of clin-
ical mental health services to veterans in the UK. Since
2011, CS has been commissioned by the NHS to provide
specialist treatment for veterans with military-related
PTSD. In an uncontrolled study, attending CS was asso-
ciated with reduced severity of PTSD symptoms after
treatment, and that these gains are maintained 6 months
later.13 Research from other countries exploring a range
of different interventions for PTSD has suggested that as
time following treatment increases, there is a reduction
in the treatment effect size.14–19
In this paper, we now report on longer term out-
comes. The outcomes are reported by following up a
sample of UK veterans a year after they had received
treatment for PTSD. We examined treatment outcome
in terms of PTSD symptom severity and a range of other
co-morbid mental health difﬁculties and functional
impairment. In addition, we assessed whether health
outcomes measured 6 months after the intervention pre-
dicted treatment response at 12 months.
METHODS
Setting
Participants for this study were recruited from CS. CS
has community outreach teams across the UK who offer
community-based assessments and low-intensity psycho-
logical and occupational supports. In addition, CS has
three residential treatment centres where veterans are
offered high-intensity interventions. Residential treat-
ment centres employ a multidisciplinary team of health-
care professionals, including psychologists, cognitive–
behaviour therapy (CBT) therapists, psychiatric nurses,
psychiatrists, occupational therapists, art therapists and
support workers.
As standard practice, when individuals were referred
to CS, they were offered a mental health assessment by a
community psychiatric nurse to ascertain their difﬁcul-
ties and to develop a treatment plan. Individuals were
then offered an assessment with a psychiatrist who,
where appropriate, made a formal diagnosis of PTSD
and provided support to treat mental health difﬁculties
with psychiatric medication. Once veterans had been
assessed and given a diagnosis of PTSD, they were
referred to a 6-week residential intervention for PTSD
that has been named the Intensive Treatment
Programme (ITP). The ITP consists of a mixture of indi-
vidual trauma-focused cognitive–behaviour therapy
(TF-CBT) sessions and group sessions. The intervention
was standardised and based on a structured manual and
ran from 09:00 to 17:00 on weekdays. In a typical day,
veterans were offered two 1.5-hour group sessions and
supported to practice newly acquired skills between ses-
sions. Over the course of each week, veterans were typic-
ally offered three individual therapy sessions. Veterans
were assigned to a closed cohort of eight individuals and
over the course of the 6 weeks were offered 55 group ses-
sions. Broadly, these groups fell within two categories:
psychoeducational groups and symptom management
groups. The psycho-education included information on
developing a psychological understanding of PTSD,
understanding the principles of CBT, providing sleep
hygiene information and information about psychiatric
medication. Examples of the symptom management
groups included behavioural activation for depression,
strategies for managing anxiety, using grounding objects
to manage dissociation, mindfulness and managing
anger. In addition, veterans were offered six weekly art
therapy sessions and a further four sessions that were led
by an Occupational Therapist, aimed to promote
engagement in meaningful activities. In accordance with
the National Institute for Health and Care Excellence
(NICE) guidance, veterans were offered a minimum of
15 individual TF-CBT sessions (90 min per session) by
psychologists or CBT therapists that focused on working
on military traumas. Completion of the ITP was deﬁned
as being present for a minimum of 5 weeks and having
attended at least 15 TF-CBT sessions. Further details of
the ITP and the other services offered by CS have been
described elsewhere.20
Participants
To improve the representativeness of our sample to the
help-seeking veteran population, participants meeting
criteria for a range of other mental health and physical
health difﬁculties, in addition to PTSD, were included.
However, individuals were excluded if there was evidence
of signiﬁcant neurological impairment that would affect
their ability to engage in psychological therapy. This did
not exclude participants with mild or moderate trau-
matic brain injuries. Further exclusion criteria included
being actively psychotic, actively dependent on alcohol
or actively suicidal, and additional support was provided
to the individual before being offered a place on the
ITP. For example, this may have included support to
engage with a local substance misuse service before
being reassessed for their suitability. Individuals were
excluded from the study if they had a formal diagnosis
of a personality disorder. Inclusion criteria for the ITP
included a diagnosis of PTSD, being a veteran (deﬁned
in the UK as completing a minimum of 1 day of active
service21) and exposure to two or more military traumas.
In addition, for those participants being prescribed psy-
chotropic medication, they had to be stable on their
medication and remain on that dose throughout the
intervention. Individuals had to have completed treat-
ment and passed the 1-year follow-up point to be
included in the data set for the current study.
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Between early 2012 and late 2014, a total of 426 veter-
ans were referred to the ITP. Of these, 401 (94%) com-
pleted treatment. Ten individuals were asked to leave
early because of using alcohol during their stay, seven
individuals had been deemed unsuitable for therapy by
the clinical team, seven individuals had to leave early
because of complicated health issues and one individual
left because his spouse experienced serious physical
health problems. There were no differences between
completers and non-completers of the ITP in terms of
their pretreatment mental health presentations.13
Finally, 352 (89%) of the 401 participants who com-
pleted treatment were successfully followed up 6 months
later, and similarly to above, we have previously shown
no pre- or post-treatment (from a study of those success-
fully followed up and those lost to follow-up) health dif-
ferences between participants followed up at 6 months
and those lost to follow-up.13 Of these 352 participants,
268 (76%) were successfully followed up 12 months after
they had completed their treatment. Interpreted by ref-
erence to the larger initial sample, 268 (67%) of the 401
participants who completed treatment during the data
collection period were successfully followed up
12 months later.
Measures
At admission, participants were asked to complete a
questionnaire providing information on a range of
demographic characteristics and baseline health out-
comes. These health outcomes were repeated at dis-
charge, and then 6 weeks, 6 months and 12 months
later.
Outcome measures
Our primary health outcome was the clinician-
completed PTSD Symptom Scale Interview (PSS-I). The
PSS-I contains 17 items that adhere to the Diagnostic
and Statistical Manual Fourth Edition22 diagnostic cri-
teria for PTSD. It can be used to assess for the presence
and the severity of PTSD.23 In addition, participants
completed a range of other outcome measures at each
time point. These included the nine-item Patient Health
Questionnaire (PHQ-9) to explore symptoms of depres-
sion,24 25 the seven-item Generalised Anxiety Disorders
measure (GAD-7),26 the ﬁve-item Dimensions of Anger
Reactions (DAR-5),27 the Alcohol Use Disorders
Identiﬁcation Test (AUDIT)28 and the Work and Social
Adjustment Scale (WSAS) to explored self-reported
functional impairment.29
Demographic characteristics
Demographic information was collected on age at admis-
sion, sex, educational achievement, employment status
and marital status. In addition, information connected
to a participant’s military career was compiled that
included service they had enlisted in (Royal Navy, Army,
Royal Air Force), enlistment type (regular or reservist),
rank (ofﬁcer or non-ofﬁcer), length of service, time
since they had left service, areas of deployment and
whether they were currently in receipt of a war pension
as a result of difﬁculties related to their military career.
Analysis
Demographic characteristics and military history were
explored. Then, because at 12-month follow-up we were
only able to contact 268 of the 352 participants who had
responded at 6 months, we explored whether there was
evidence of a response health bias at 12 months. Linear
regression models were ﬁtted to assess 6-month health
outcomes comparing participants who had been success-
fully followed up or not at 12 months. These models
were repeated and adjusted for all of the 6-month
health outcomes.
The next stage of the analysis was to explore whether
there were changes in health outcome scores over the
course of data collection. Random slope non-linear
growth models with a ﬁxed coefﬁcient of time squared
were ﬁtted to explore the longitudinal health and func-
tional impairment data collected at pretreatment, end of
treatment, 6-week, 6-month and 12-month follow-ups.30
These analyses were repeated and adjusted for age and
employment status. These variables, along with the ﬁxed
coefﬁcient of time squared, were found to improve the
ﬁt of the models using likelihood ratio tests. The sample
used for this analysis was the 401 participants who had
completed the ITP. This analysis was repeated but
restricted to only the 268 participants who had been fol-
lowed up 12 months after treatment. The rationale for
this was to explore, if there was evidence of a health bias
in those lost to follow-up at 12 months, whether this
affected the results by comparing between the two
models. Six- and 12-month Cohen d’s effect sizes were
calculated incorporating correlations between pre- and
post-treatment PSS-I scores.31 32
The ﬁnal stage of the analysis assessed whether the
secondary outcomes we collected at 6-month follow-up
were predictors of PTSD outcomes at 12-month
follow-up. Univariate linear regression models were
ﬁtted between each 6-month outcome and 12-month
PSS-I scores. Three adjusted models were then ﬁtted. In
Model 1, age and employment status were included, and
then Model 2 was further adjusted by adding in the
other health outcomes. Model 3 mirrored the previous
one but with the addition of 6-month PSS-I scores.
Analyses were conducted using Stata V.13 (StataCorp,
College Station, Texas, USA).
Ethics
Ethics approval for this study was granted by the CS
ethics committee. Participants provided written consent
to take part in treatment and the research.
RESULTS
The characteristics of the sample are described in
table 1. Forty-two per cent of the sample was aged over
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45 years, 33% were aged between 44 and 35 years, and
25% were aged <35 years. The mean age was 43.1 years.
The sample was predominately male (98%), had lower
levels of educational achievement (88%), had served in
the Army (84%), had been in the lower ranks (90%)
and served within combat roles (77%). Thirty-eight per
cent of the sample reported being employed, 57% in a
relationship, 43% were in receipt of a war pension and
37% reported that it had not been their decision to
leave the military (eg, they had been medically dis-
charged). Sixty per cent of the participants had left the
military 10 or more years previously (the mean time
period was 14.7 years). The majority of the participants
reported that they had deployed to at least one conﬂict
zone during the military service, and 41% reported that
they had deployed to two or more conﬂicts zones. The
most frequently endorsed deployment was to Northern
Ireland (55%), followed by operations to Iraq since 2003
(31%), Afghanistan since 2001 (22%), the Balkans
(22%) and ﬁnally the 1991 Gulf War (15%).
Table 2 observed whether 6-month health scores differed
between participants who were followed up or not at
12 months to assess whether there was a health bias in
those lost to follow-up. No signiﬁcant differences were
noted for ﬁve of the six health outcomes used in the study.
However, participants who were lost to follow-up at
12 months were signiﬁcantly more likely to have higher
scores on the PSS-I at 6 months than those we were able to
make contact with. This suggests that severity of PTSD symp-
toms predicted being lost to 12-month follow-up, though
the differences were modest (scores of 23.7 vs 27.6).
The next stage of the analysis was to explore the longi-
tudinal health outcomes from pretreatment to
12 months post-treatment (see table 3). Our primary
outcome measure was the PSS-I (PTSD). Signiﬁcant
reductions in the severity of PTSD were observed
between pretreatment and 12 months post-treatment.
Modest reductions in the severity of the other health
outcomes were also observed. In table 2, we reported
that participants who were lost to follow-up at this time
point were more likely to have modestly higher PSS-I
scores at 6 months. Because of this, we were concerned
about bias limiting our ﬁndings. Model 1 contained all
participants available at each time point, and Model 2
was restricted to only those who responded at the ﬁnal
data collection time point. Only marginal differences
were observed in the β-coefﬁcients between these
models (eg, PSS-I: −11.7 vs −11.9). In an additional ana-
lysis, we observed reductions in the severity of PTSD
symptoms in 87% of the participants 6 months after
treatment, and this remained roughly consistent at 83%
at the 1-year post-treatment time point. An effect size of
1.04 was found at 6 months and 1.03 at 12 months.
The results in table 4 observed whether health outcomes
at 6-month follow-up predicted PTSD severity at
12 months. In the unadjusted regression, and when
adjusted for age and employment status, higher scores on
all of the health outcome measures at 6 months were asso-
ciated with worse PSS-I scores at 12 months. Following
adjustment for each of the other health outcomes, higher
scores on the measures of depression, alcohol problems
and functional impairment remained signiﬁcant predic-
tors of higher PTSD scores at 12 months. When this ana-
lysis was repeated, and further adjusted for 6-month PSS-I
scores, only alcohol problems and functional impairment
remain as signiﬁcantly associated with poorer PTSD treat-
ment response at 12 months.
DISCUSSION
In this study, we provided evidence for positive longer
term treatment responses in a sample of UK veterans
Table 1 Demographic characteristics
Variable Number* (%)
Total completed ITP 401
Age group
<35 100 (25)
35–44 132 (33)
>45 169 (42)
Sex
Male 394 (98)
Female 7 (2)
Education
Low (O levels or none) 346 (88)
High (A levels or above) 49 (12)
Relationship status
In a relationship 227 (57)
Single 171 (43)
Employment status
Working 146 (38)
Not working 234 (62)
Receipt of war pension
No 223 (57)
Yes 166 (43)
Service
Royal Navy 41 (10)
Army 333 (84)
Royal Air Force 23 (6)
Role in military
Non-combat 89 (23)
Combat 302 (77)
Last rank
Officer 38 (10)
Other ranks 359 (90)
Type of discharge from military
Voluntary 245 (63)
Non-voluntary 144 (37)
Years since left the military
1–9 159 (40)
10–19 108 (27)
20–29 89 (23)
30+ 39 (10)
Number of deployments to conflicts zones
1 or 2 230 (59)
3+ 162 (41)
*Numbers may not add up to 401 because of missing data.
ITP, Intensive Treatment Programme.
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treated for PTSD. The intervention they received was a
standardised 6-week residential treatment programme
that consisted of a mixture of closed groups and individ-
ual TF-CBT sessions. Improvements post-treatment were
noted at the end of treatment, and evidence was pre-
sented to suggest that these gains were maintained for
the majority 12 months later. Modest improvements in
our secondary outcomes of co-morbid difﬁculties such
as depression, anxiety, problems with anger, alcohol dif-
ﬁculties and self-reported functional impairment that
were maintained 12 months after participants completed
treatment were observed. Associations were noted
between higher levels of depression or functional
impairment post-treatment and worse PTSD treatment
outcomes at 12 months.
It is frequently observed in the psychological therapy
literature that treatment gains reduce over
time.4 14 15 17 18 33 With this in mind, we were encour-
aged that the 12-month post-treatment response pre-
sented in this paper was roughly equivalent to the
6-month post-treatment response for this intervention
that have been published previously (PSS-I 6-month β
−12.9 (95% CI −14.5 to −11.4) vs 12-month β −11.7
(95% CI −13.1 to −10.7). Furthermore, in the current
study, we observed an effect size of 1.03 at 12 months,
which was very similar to the effect size at 6 months
(1.04), both of which can be interpreted as evidence of
large effect sizes.31 As there was little difference between
these effect sizes, this provides positive support for the
longer term beneﬁts of the intervention, and our ﬁnd-
ings compare favourably in terms of effects sizes with
studies of Australian and US veterans treated for PTSD
(0.9 and 0.7–0.9, respectively) (M Creamer, Auditing
Combat Stress’s performance: an evaluation of the ITP,
2015, Personal Communication). While we have
reported signiﬁcant reductions in PTSD severity
12 months after completing treatment, the majority of
participants’ (63.8%) scores on the PSS-I indicated that
they met criterion for probable PTSD. This rate seems
equivalent to a study of Canadian veterans who received
treatment for PTSD and were also followed up
12 months later, which reported that even with signiﬁ-
cant reductions in the severity of presentations, over half
of their (57.8%) sample still met criteria for probable
PTSD.34
Previous studies have indicated that symptoms of
depression and anxiety are predictors of worse treatment
response in veterans with PTSD.33 35 The current study
Table 2 Health characteristics of those followed up or not at 12 months post-treatment
Six-month post-treatment scores
Followed up Not followed up Adjusted β
Mean (SD) Mean (SD) (95% CI)
PTSD (PSS-I) 23.7 (12.4) 27.6 (10.8) 1.03 (1.00 to 1.05)*
Depression (PHQ-9) 13.8 (7.09) 15.6 (6.61) 1.03 (0.99 to 1.07)
Generalised anxiety (GAD-7) 12.2 (5.76) 13.4 (5.74) 1.02 (0.97 to 1.08)
Anger (DAR-5) 9.44 (6.39) 9.53 (5.40) 1.00 (0.95 to 1.05)
Alcohol (AUDIT) 7.41 (8.29) 7.56 (8.22) 1.01 (0.97 to 1.04)
Functioning (WSAS) 21.9 (9.89) 24.4 (8.86) 1.02 (0.99 to 1.05)
*p≤0.05 β adjusted for all other variables in table.
AUDIT, Alcohol Use Disorders Identification Test; DAR-5, five-item Dimensions of Anger Reactions; GAD-7, Generalised Anxiety Disorders
measure; PSS-I, PTSD Symptom Scale Interview; PTSD, post-traumatic stress disorder; WSAS, Work and Social Adjustment Scale.
Table 3 Twelve-month post-treatment health outcomes
Adjusted β
Admission
score
12-Month
score Unadjusted β Model 1 Model 2
Mean (SD) Mean (SD) (95% CI) (95% CI) (95% CI)
PTSD (PSS-I) 36.5 (7.40) 24.9 (11.6) −11.7 (−12.6 to −10.7) −11.7 (−12.7 to −10.6) −11.9 (−13.1 to −10.7)
Depression (PHQ-9) 17.1 (5.18) 15.0 (8.45) −4.21 (−4.82 to −3.60) −4.23 (−4.86 to −3.60) −4.08 (−4.83 to −3.33)
Generalised anxiety
(GAD-7)
15.6 (4.78) 13.0 (6.71) −4.26 (−4.82 to −3.69) −4.25 (−4.83 to −3.66) −4.32 (−5.04 to −3.59)
Anger (DAR-5) 11.3 (5.16) 9.41 (5.56) −2.61 (−3.08 to −2.15) −2.57 (−3.06 to −2.09) −2.58 (−3.17 to −2.00)
Alcohol (AUDIT) 8.92 (8.42) 7.21 (8.01) −1.02 (−1.51 to −0.53) −1.07 (−1.56 to −0.57) −1.21 (−1.77 to −0.65)
Functioning (WSAS) 25.2 (8.24) 22.3 (10.3) −2.87 (−3.69 to −2.04) −2.97 (−3.81 to −2.13) −2.92 (−3.94 to −1.91)
Model 1 is β adjusted for age and employment status. Model 2 is the same as Model 1 but restricted to only participants followed up
successfully at 12 months.
AUDIT, Alcohol Use Disorders Identification Test; DAR-5, five-item Dimensions of Anger Reactions; GAD-7, Generalised Anxiety Disorders
measure; PSS-I, PTSD Symptom Scale Interview; PTSD, post-traumatic stress disorder; WSAS, Work and Social Adjustment Scale.
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examined whether post-treatment factors predicted
PTSD outcomes at 1-year follow-up. Mental health
co-morbidities did not seem to be signiﬁcant predictors,
while functional impairment and problems with alcohol
were. It could be that while there may be remission in
PTSD symptoms, this does not equate to global improve-
ments in all areas of veterans lives and further support is
needed to tackle alcohol dependency and long-term
functional impairment that may have resulted from
living with chronic symptoms of PTSD. Overall, the
scores on the AUDIT exploring problems with alcohol
are lower than may have been expected, compared to
populations of UK veterans with mental health difﬁcul-
ties.36 37 This may be explained by the criteria that
excluded potential participants if they had harmful
dependent drinking patterns.
Strengths and weaknesses
This study proﬁted from using a standard intervention
that had been manualised to increase our conﬁdence in
ﬁdelity of the treatment received by participants.
Furthermore, the intervention had high rates of comple-
tion, and we were able to follow up a large proportion
of our participants. Where participants were lost to
follow-up, we were able to assess data collection at previ-
ous time points to explore bias. To improve the repre-
sentativeness of our sample, they were drawn from
consecutive referrals to the ITP. This means that while
PTSD was the primary diagnosis for participants, indivi-
duals with other co-morbid mental health presentations,
dual diagnosis alcohol problems and functional impair-
ment should also have been represented in our sample.
For example, the mean pretreatment AUDIT score was
8.92 (95% CI 8.09–9.76), which indicates that the major-
ity of participants met criteria for hazardous drinking.
As such, the sample employed for the current study
should be representative of the clinical population of
help-seeking veterans with PTSD. However, certain sub-
groups were not represented. For example, one of the
exclusion criteria was having a diagnosis of a personality
disorder. In addition, only a minority (2%) of the
sample was women compared to ∼10% in the current
UK Armed Forces.10
The current study did not employ a randomised con-
trolled trial (RCT) design, and we acknowledge the lim-
itations this entails. As such, caution is needed when
interpreting the results presented in the paper because
we were unable to use randomisation and a control con-
dition to deal with confounding from unmeasured vari-
ables. The rationale for the study design used was that
CS had been commissioned to provide a clinical service
to support UK veterans with PTSD that was based on
existing evidence from Australia,14 and we have taken
advantage of this opportunity to evaluate the impact of
this intervention. A possibility exists that the gains
observed within the current study resulted from a
natural recovery from PTSD. However, participants for
this study reported that they had left the military on
average 14.7 years before being offered the ITP. We have
used time since leaving the forces as a proxy measure
for time since trauma (because exposure to military
trauma was an inclusion criterion). As such, this pro-
vided evidence against the gains reported being as a
result of spontaneous recovery as participants had been
living with their symptoms for signiﬁcant periods of
time.
It was noted that participants whose symptoms of
PTSD were worse at 6-month follow-up were more likely
to be lost to follow-up at 12 months. This could have
introduced bias into the results presented in this paper
by deﬂating the mean PSS-I score at 12 months as indivi-
duals with higher PSS-I were more likely not to have
responded at this time point. To attempt to mitigate this,
we conducted two identical analyses to explore
12-month treatment outcomes. The ﬁrst used the full
sample at each time point to include participants who
were later lost to follow-up, and the second was
restricted to only participants successfully followed up at
12 months. Only modest differences were observed
between the β coefﬁcient in these two models, which
suggests that any bias between those lost to follow-up or
not at 12 months did not adversely impact our results.
Our results suggest a statistically signiﬁcant reduction
of 11.7 points on the PSS-I between the pretreatment
and 12-month follow-up. This does not necessarily
equate to a change in probable PTSD diagnosis as there
Table 4 Relationships between 6-month post-treatment health outcomes and 12-month post-treatment PTSD scores
Unadjusted β (95% CI)
Adjusted β (95% CI)
Model 1 Model 2 Model 3
Depression (PHQ-9) 0.80 (0.62 to 0.98)* 0.79 (0.60 to 0.98)* 0.35 (0.07 to 0.63)* 0.15 (−0.12 to 0.41)
Generalised anxiety (GAD-7) 0.95 (0.73 to 1.18)* 0.93 (0.70 to 1.16)* 0.26 (−0.10 to 6.63) 0.05 (−0.40 to 0.29)
Anger (DAR-5) 0.52 (0.30 to 0.75)* 0.55 (0.32 to 0.78)* 0.08 (−0.33 to 0.17) 0.03 (−0.38 to 0.07)
Alcohol (AUDIT) 0.24 (0.07 to 0.42)* 0.26 (0.07 to 0.44)* 0.19 (0.04 to 0.35)* 0.18 (0.03 to 0.32)*
Functioning (WSAS) 0.60 (0.47 to 0.73)* 0.61 (0.47 to 0.74)* 0.37 (0.20 to 0.54)* 0.24 (0.08 to 0.41)*
Model 1 is β adjusted for age and employment status. Model 2 is additionally adjusted for 6-month health outcomes listed above. Model 3, in
addition to Model 2, is adjusted for 6-month post-treatment PSS-I score.
*p≤0.05.
AUDIT, Alcohol Use Disorders Identification Test; DAR-5, five-item Dimensions of Anger Reactions; GAD-7, Generalised Anxiety Disorders
measure; PSS-I, PTSD Symptom Scale Interview; PTSD, post-traumatic stress disorder; WSAS, Work and Social Adjustment Scale.
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was still a high burden of symptoms being reported by
study participants. Using existing cut-offs for the PSS-I
would suggest that the mean 12-month post-treatment
score would be above the cut-off for meeting probable
case criterion. However, these cut-offs have not been vali-
dated within this population, which makes interpretation
difﬁcult. To address this, we are currently collecting data
to validate various measures of PTSD against the CAPS-5
for UK veterans.
No information was available about the psychiatric
medication participants were prescribed. However, one
of the inclusion criteria for a referral to the ITP was that
individuals had to be stable on psychiatric medication.
This provides some evidence to suggest that any gains
observed resulted from completing the ITP rather than
psychiatric medication.
CONCLUSIONS
Meta-analyses have suggested that veterans have less
favourable responses to treatment for PTSD than other
groups.1–3 Given this, it is encouraging that data pre-
sented in this paper suggest the longer term beneﬁts of
a 6-week residential treatment for veterans with PTSD.
The intervention was delivered within veteran-speciﬁc
clinics using a combination of psychoeducational and
symptom management groups and individual TF-CBT.
Our results point to a statistically signiﬁcant reduction in
the burden of PTSD symptoms for the participants in
our sample and that these gains were maintained
12 months after treatment. More modest treatment
responses were noted for a range of other mental health
difﬁculties, problems with alcohol and functional impair-
ment. Our ﬁndings suggest the importance of continu-
ing to support veterans after they have completed
treatment to maintain gains. In particular, individuals
experiencing problems with alcohol, and where there is
evidence of high levels of functional impairment,
appear to be groups that could proﬁt from further
input. While the results presented in this paper may be
cause for cautious optimism, further work is needed to
explore the intervention described using an RCT to
overcome some of the limitations discussed above.
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